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In 1975, Reid et al.
1 discovered catecholaminergic polymorphic ventricular tachy-
cardia (CPVT). CPVT is known to cause syncope or sudden cardiac death, and the
three distinguishing features of CPVT has subsequently been described by
Coumel and associates.
2 These features of CPVT are as follows: 1) exercise- or
emotion-induced severe ventricular tachyarrhythmias; 2) a typical pattern of
bidirectional ventricular tachycardia with a normal resting ECG; and 3) a
structurally normal heart. Recent reports suggest that CPTV is a genetic disease
related to the mutation of 2 genes: mutations in cardiac ryanodine receptor gene
(RYR2) or calsequestrin 2 gene (CASQ2) lead to an increase in the intracellular
Ca
++ concentration, resulting in arrhythmia due to a cascade of delayed afterdepol-
arization and triggered activity.
3-5
An 11-year-old female patient with a prior history of cardiac arrest arrived at the
emergency room (ER) 35 minutes after losing consciousness. Her mother had
immediately administered basic life support. The patient was born in the 40th
gestational week by normal spontaneous vaginal delivery and weighed 4.0 kg.
There was no specific family history of syncope or sudden cardiac death. Six years
ago, she experienced a brief syncopal episode. Electroencephalography (EEG) at
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CASE REPORTthat time showed no specific abnormality. Six months after
this first event, she was admitted to the ER for sudden loss
of consciousness. Ventricular fibrillation (VF) was noted,
and the normal sinus rhythm was restored by defibrillation.
Neither delta wave nor QT interval prolongation was observ-
ed on a resting electrocardiogram (ECG) (Fig. 1). Echo-
cardiography did not reveal any structural abnormalities,
and Holter monitoring did not reveal specific arrhythmias.
Brain magnetic resonance imaging (MRI) revealed no
abnorzmalities. EEG was remarkable for dysrrhythmic
waves and low amplitude voltage compatible with hypoxic
encephalopathy. Although the definite cause of VF was not
determined, it was recommended that the patient takes a
beta-blocker (atenolol, 12.5 mg bid). She then underwent
rehabilitation for cognitive function defects which resulted
from hypoxic brain damage. She did not suffer any more
attacks and stopped taking atenolol after several years.
Upon this ER arrival, the patient was unconscious, pul-
seless, and without spontaneous respirations. Blood pressure
was undetectable, and her body temperature was 36.5˚C.
The initial ECG showed VF. Normal sinus rhythm was
restored after 2 monophasic direct current defibrillations at
200 J (Fig. 2). On chest X-ray, no cardiomegaly or pulmo-
nary congestion was observed. The laboratory test results
were as follows: white blood cell count, 12,400/mm
3; hemo-
globin, 14.5 g/dL; platelet count, 188,000/mm
3; sodium,
138 mmol/L; potassium, 5.7 mmol/L; chloride, 111 mmol/L;
ionized calcium, 1.42 mmol/L; ionized magnesium, 1.06
mmol/L; creatine kinase, 124 U/L; and creatine kinase-MB,
0.9 ng/mL. An arterial blood gas test revealed the following:
pH 7.13; PaCO2, 55.5 mmHg; PaO2, 59.8 mmHg; HCO3,
17.7 mmol/L; and SaO2, 80.1%. 
After defibrillation and intubation, the patient was moved
to the coronary care unit (CCU). During nasogastric tube
insertion, VF redeveloped. Sinus rhythm was successfully
restored by 2 defibrillations at 200 J. A review of telemetry
monitoring in the CCU revealed that sinus tachycardia
precipitated bidirectional ventricular tachycardia that in turn
degenerated into VF (Fig. 3).
The patient was diagnosed with CPVT accompanied by
typical bidirectional ventricular tachycardia which was
triggered by sinus tachycardia. After intravenously admi-
nistered beta-blocker (labetalol, 10 mg), tachyarrhythmia
was no longer observed. After stabilization, echocardio-
Catecholaminergic Ventricular Tachycardia
Yonsei Med J   http://www.eymj.org    Volume 50   Number 3   June 2009 449
Fig. 1.Six years ago, the resting electrocardiogram showed normal sinus rhythm without delta wave nor QT interval prolongation (QTc 399 ms).
Fig. 2.The initial rhythm strip in emergency department showed ventricular defibrillation. After 200 J defibrillation (arrow), sinus rhythm was restored.graphy revealed an ejection fraction of 68% without any
structural abnormalities. She was prescribed an oral beta-
blocker (metoprolol, 100 mg bid) and discharged from
hospital. She is currently being followed up.
Since it was first discovered in 1975, CPVT has been report-
ed as a cause of syncope, ventricular arrhythmias and sudden
cardiac death. CPVT typically manifests as syncope between
7 and 9 years of age,
6 but sudden death may be the first
presentation. In 30% of CPVT patients, there is family
history of sudden death before the age of 40.
7 Patients with
RYR2 mutation become symptomatic earlier, and men are at
higher risk of cardiac events.
8 CPVT is associated with two
genetic mutations, RYR2 and CASQ2. RYR2 is inherited in
an autosomal dominant pattern and mediates the release of
calcium from the sarcoplasmic reticulum that is required for
myocardial contraction.
9 The RYR2 mutation increases
calcium release and can trigger life-threatening ventricular
arrhythmias. A second genetic form of CPVT, with an auto-
somal recessive inheritance, involves CASQ2. The CASQ2
protein, which serves as the major calcium reservoir within
the sarcoplasmic reticulum, has an ability to bind extremely
large amounts of calcium. The mutated protein may alter
the calcium content within the sarcoplasmic reti-culum,
alter the function of the ryanodine receptor, or impair the
calcium release process.
10
CPVT is difficult to diagnose, because ECG is normal in
the absence of symptoms and echocardiography shows no
specific findings. A typical finding on ECG is ventricular
tachycardia with 180-degree alternation of the QRS axis
(bidirectional tachycardia). CPVT is not inducible by pro-
grammed electrical stimulation.
6 In patients suspected to have
this disease, the arrhythmia must be recorded by Holter moni-
toring or induced by exercise treadmill testing. In the present
patient, sinus tachycardia appeared to have been induced by
the insertion of the nasogastric tube, and this in turn might
have given rise to the bidirectional ventricular tachycardia
that finally degenerated into VF. This is the typical course
of CPVT, and activity triggering by a burst in the sympathetic
tone is the main mechanism for this process. Hence, the
focus of treatment is to suppress the adrenergic activity,
therefore, beta-blockers are the most important drugs in the
treatment of CPVT. Beta-blockers are effective for acute
phase and maintenance treatment.
11 However, if the symp-
toms recur despite the administration of a sufficient dose of
beta-blockers, an implantable cardioverter/defibrillator must
be employed. Our patient received a beta-blocker. To opti-
mize the dosage of beta-blocker, the isoproterenol challenge
test was planned for the patient’s neurologic sequela, but
the test was not performed because the patient’s parents did
not approve. A genetic study for the patient and her family
was also refused.
Syncope or sudden cardiac death in childhood might occur
due to other arrhythmogenic entities. These include arrhyth-
mogenic right ventricular cardiomyopathy (ARVC), Brugada
syndrome, long QT syndrome (LQT), particularly LQT type
1, pre-excitation syndrome, commotio cordis, and Andersen-
Tawil syndrome (ATS). ARVC has structural abnormalities
of heart and does not usually exhibit ventricular arrhythmias
when provoked by an exercise stress test. Brugada syndrome
is characterized by electrocardiographic findings of right
bundle branch block and ST-segment elevation in leads V1
to V3 at resting ECG. In LQT, some patients do not develop
QT prolongation, and it may be explained by repolarization
reserve (variable redundancy of repolarizing currents), and
resemble to CPVT.
12,13 However, differential diagnosis is
possible because LQT type 1 does not usually exhibit pro-
gressive polymorphic ventricular arrhythmias during graded
exercise. Furthermore, there exist the delta wave in pre-
excitation syndrome and a history of blunt chest trauma in
commotio cordis. ATS is an inherited arrhythmogenic disor-
der caused by mutations in the KCNJ2 gene. Patients may
develop bidirectional ventricular tachycardia, similar to that
in CPVT. Although ATS may be similar to CPVT, it is con-
sidered as a distinct disorder, because of extracardiac mani-
festations (e.g., periodic paralysis and distinctive facial
features), the low risk of sudden cardiac death, and the lack
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DISCUSSION
Fig. 3. The rhythm strip in coronary care unit. The sinus tachycardia (arrow) triggered bidirectional ventricular tachycardia (arrow-heads). Then, the bidirectional
ventricular tachycardia degenerated into ventricular fibrillation.of relationship between arrhythmia and elevated sympa-
thetic tones.
CPVT is a potentially fatal disorder that is usually observ-
ed in childhood. As in our case, patients presenting with
sudden cardiac arrest can be mistaken as idiopathic VF and
suffer from the sequelae of resuscitation. Therefore, clinicians
should carefully analyze the triggering of factors VF in
healthy individuals.
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